Autoantibodies to Osteoprotegerin Are Associated with Low Hip Bone Mineral Density and History of Fractures in Axial Spondyloarthritis: A Cross-Sectional Observational Study

Overview

Journal Calcif Tissue Int

Specialty Pathology

Date 2017 May 24

PMID 28534161

Citations 14

Authors

Barbara Hauser

Sizheng Zhao

Micaela R Visconti

Philip L Riches

William D Fraser

Isabelle Piec

Nicola J Goodson

Stuart H Ralston

Affiliations

Soon will be listed here.

Abstract

Osteoporosis is a recognised complication of axial spondyloarthritis (axSpA) and is thought to be due to functional impairment and the osteoclast-activating effects of proinflammatory cytokines. The development of autoantibodies to OPG (OPG-Ab) has been associated with severe osteoporosis and increased bone resorption in rheumatoid arthritis. In this study, we screened for the presence of OPG-Ab in axSpA and reviewed their clinical significance. We studied 134 patients, recruited from two centres in the United Kingdom. Their mean age was 47.5 years and 75% were male. Concentrations of OPG-Ab were related to bone mineral density (BMD) and fracture history using linear and logistic regression models adjusting for age, gender, disease duration and activity, body mass index and bisphosphonate use. We detected OPG-Ab in 11/134 patients (8.2%). Femoral neck and total hip BMD were significantly reduced in OPG-Ab positive patients (0.827 vs. 0.967 g/cm, p = 0.008 and 0.868 vs. 1.028 g/cm, p = 0.002, respectively). Regression analysis showed that the presence of OPG-Ab was independently associated with total hip osteopenia (OR 24.2; 95% CI 2.57, 228) and history of fractures (OR 10.5; 95% CI 2.07, 53.3). OPG-Ab concentration was associated with total hip BMD in g/cm (ß = -1.15; 95% CI -0.25, -0.04). There were no associations between OPG-Ab concentration and bone turnover markers, but free sRANKL concentrations were lower in OPG-Ab-positive patients (median 0.04 vs. 0.11 pmol/L, p = 0.050). We conclude that OPG-Ab are associated with hip BMD and fractures in axSpA suggesting that they may contribute to the pathogenesis of bone loss in some patients with this condition.

Citing Articles

Bone Involvement in Rheumatoid Arthritis and Spondyloartritis: An Updated Review.

Orsini F, Crotti C, Cincinelli G, Di Taranto R, Amati A, Ferrito M Biology (Basel). 2023; 12(10).

PMID: 37887030 PMC: 10604370. DOI: 10.3390/biology12101320.

Osteoimmunology of Spondyloarthritis.

Fassio A, Atzeni F, Rossini M, DAmico V, Cantatore F, Chimenti M Int J Mol Sci. 2023; 24(19).

PMID: 37834372 PMC: 10573470. DOI: 10.3390/ijms241914924.

How Has Molecular Biology Enhanced Our Undertaking of axSpA and Its Management.

Fatica M, DAntonio A, Novelli L, Triggianese P, Conigliaro P, Greco E Curr Rheumatol Rep. 2022; 25(1):12-33.

PMID: 36308677 PMC: 9825525. DOI: 10.1007/s11926-022-01092-4.

Effects of Biological/Targeted Therapies on Bone Mineral Density in Inflammatory Arthritis.

Chen T, Chang K, Su K Int J Mol Sci. 2022; 23(8).

PMID: 35456929 PMC: 9029148. DOI: 10.3390/ijms23084111.

B Cell Involvement in the Pathogenesis of Ankylosing Spondylitis.

Wilbrink R, Spoorenberg A, Verstappen G, Kroese F Int J Mol Sci. 2021; 22(24).

PMID: 34948121 PMC: 8703482. DOI: 10.3390/ijms222413325.

References

Hui S, Gao S, Zhou X, JOHNSTON Jr C, Lu Y, Gluer C . Universal standardization of bone density measurements: a method with optimal properties for calibration among several instruments. J Bone Miner Res. 1997; 12(9):1463-70. DOI: 10.1359/jbmr.1997.12.9.1463. View

Montala N, Juanola X, Collantes E, Munoz-Gomariz E, Gonzalez C, Gratacos J . Prevalence of vertebral fractures by semiautomated morphometry in patients with ankylosing spondylitis. J Rheumatol. 2011; 38(5):893-7. DOI: 10.3899/jrheum.100851. View

Real A, Gilbert N, Hauser B, Kennedy N, Shand A, Gillett H . Characterisation of osteoprotegerin autoantibodies in coeliac disease. Calcif Tissue Int. 2015; 97(2):125-33. DOI: 10.1007/s00223-015-0023-4. View

Riches P, McRorie E, Fraser W, Determann C, Hof R, Ralston S . Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. N Engl J Med. 2009; 361(15):1459-65. DOI: 10.1056/NEJMoa0810925. View

Kanis J, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E . FRAX and its applications to clinical practice. Bone. 2009; 44(5):734-43. DOI: 10.1016/j.bone.2009.01.373. View

van der Weijden M, van der Horst-Bruinsma I, van Denderen J, Dijkmans B, Heymans M, Lems W . High frequency of vertebral fractures in early spondylarthropathies. Osteoporos Int. 2011; 23(6):1683-90. DOI: 10.1007/s00198-011-1766-z. View

van der Linden S, VALKENBURG H, Cats A . Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27(4):361-8. DOI: 10.1002/art.1780270401. View

Will R, Palmer R, Bhalla A, Ring F, Calin A . Osteoporosis in early ankylosing spondylitis: a primary pathological event?. Lancet. 1989; 2(8678-8679):1483-5. DOI: 10.1016/s0140-6736(89)92932-2. View

Hauser B, Riches P, Gilchrist T, Visconti M, Wilson J, Ralston S . Autoantibodies to osteoprotegerin are associated with increased bone resorption in rheumatoid arthritis. Ann Rheum Dis. 2015; 74(8):1631-2. DOI: 10.1136/annrheumdis-2014-207219. View

10.

Stern A, Laughlin G, Bergstrom J, Barrett-Connor E . The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol. 2007; 156(5):555-62. PMC: 2642656. DOI: 10.1530/EJE-06-0753. View

11.

Lu Y, Fuerst T, Hui S, Genant H . Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. Osteoporos Int. 2001; 12(6):438-44. DOI: 10.1007/s001980170087. View

12.

Boyce B, Xing L . Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008; 473(2):139-46. PMC: 2413418. DOI: 10.1016/j.abb.2008.03.018. View

13.

Wendling D, Cedoz J, Racadot E, Dumoulin G . Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine. 2007; 74(3):304-5. DOI: 10.1016/j.jbspin.2006.11.005. View

14.

Allali F, Breban M, Porcher R, Maillefert J, Dougados M, Roux C . Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis. 2003; 62(4):347-9. PMC: 1754495. DOI: 10.1136/ard.62.4.347. View

15.

Donnelly S, Doyle D, Denton A, Rolfe I, McCloskey E, Spector T . Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis. 1994; 53(2):117-21. PMC: 1005263. DOI: 10.1136/ard.53.2.117. View

16.

Cooper C, Carbone L, Michet C, Atkinson E, OFallon W, Melton 3rd L . Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol. 1994; 21(10):1877-82. View

17.

Ghozlani I, Ghazi M, Nouijai A, Mounach A, Rezqi A, Achemlal L . Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone. 2009; 44(5):772-6. DOI: 10.1016/j.bone.2008.12.028. View

18.

Ralston S, Urquhart G, Brzeski M, Sturrock R . Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. BMJ. 1990; 300(6724):563-5. PMC: 1662343. DOI: 10.1136/bmj.300.6724.563. View

19.

Rudwaleit M, Jurik A, Hermann K, Landewe R, van der Heijde D, Baraliakos X . Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis. 2009; 68(10):1520-7. DOI: 10.1136/ard.2009.110767. View

20.

van der Weijden M, van Denderen J, Lems W, Heymans M, Dijkmans B, van der Horst-Bruinsma I . Low bone mineral density is related to male gender and decreased functional capacity in early spondylarthropathies. Clin Rheumatol. 2010; 30(4):497-503. PMC: 3062761. DOI: 10.1007/s10067-010-1538-8. View